HD204: Analytical biocomparability and clinical trial I progression of bevacizumab.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e15014
Abstract: e15014 Background: Prestige Biopharma Pte Ltd is developing HD204, a biosimilar of the EU-approved and US-licensed Bevacizumab (Avastin) that is approved treatment for a variety of tumour types. Bevacizumab is a recombinant humanized monoclonal antibody… read more here.
Keywords: hd204 analytical; biocomparability clinical; biocomparability; analytical biocomparability ... See more keywords